Credit Suisse lowered their price target on shares of Spectrum Pharma (NASDAQ: SPPI) from $15.00 to $7.00 in a research note issued on Wednesday. The firm currently has a “neutral” rating on the stock.

A number of other analysts have also recently weighed in on SPPI. Analysts at WallachBeth downgraded shares of Spectrum Pharma from a “buy” rating to a “sell” rating in a research note to investors on Wednesday. They now have a $5.50 price target on the stock, down previously from $20.00. Separately, analysts at RBC Capital raised their price target on shares of Spectrum Pharma from $17.00 to $19.00 in a research note to investors on Friday, February 22nd. Finally, analysts at Zacks downgraded shares of Spectrum Pharma from a “neutral” rating to an “underperform” rating in a research note to investors on Monday, February 11th. They now have a $11.80 price target on the stock.

Four research analysts have rated the stock with a buy rating, and one has issued a hold rating to the company. Spectrum Pharma presently has a consensus rating of “buy” and an average price target of $21.00.

Shares of Spectrum Pharma opened at 12.43 on Wednesday. Spectrum Pharma has a 52 week low of $9.31 and a 52 week high of $17.48. The stock’s 50-day moving average is currently $11.83. The company has a market cap of $733.3 million and a P/E ratio of 8.51.

Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.